Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented:
“Demonstrating the extended stability of the cream formulation was a key step to commencing the human study. This remains on track to start this month.”
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
SkinBioTherapeutics plc (LON: SBTX), a life science company focused on skin health, today provided an update to its announcement of 16 August 2018. The stability criteria required for its human study has been met and the Company expects to commence the study in September as planned.